Benzinga · Mar 4, 2026
EO
NASDAQ · EOLS
Evolus, Inc.
Healthcare · Drug Manufacturers - Specialty & Generic
$8.88
Up+$0.00 (+0.00%)
Updated Aug 31, 2026, 12:05 PM
SID Score
6.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 448.23M
- P/E ratio
- -7.64
- Dividend yield
- 0.00%
- 52-week range
- $3.86 – $9.12
- Volume
- 1.06M
- Avg. volume
- 1.3M
Price performance
EOLS price history
1M range · 20 trading sessions · Daily adjusted prices
EOLS closed at $8.88 after 20 trading sessions, up 46.78% for the selected period.
- Last close
- $8.88
- Period change
- +46.78%
- Period low
- $6.05
- Period high
- $8.98
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 28, 2026 | $8.84 | $8.94 | $8.595 | $8.88 | 1.06M |
| Aug 27, 2026 | $8.78 | $9.035 | $8.60 | $8.88 | 1.19M |
| Aug 26, 2026 | $8.86 | $9.08 | $8.77 | $8.78 | 1.51M |
| Aug 25, 2026 | $8.72 | $9.12 | $8.70 | $8.975 | 1.8M |
| Aug 24, 2026 | $8.39 | $8.82 | $8.2596 | $8.78 | 1.32M |
| Aug 21, 2026 | $8.35 | $8.48 | $8.235 | $8.39 | 582.72K |
| Aug 20, 2026 | $8.55 | $8.55 | $8.32 | $8.35 | 663.32K |
| Aug 19, 2026 | $8.22 | $8.69 | $8.22 | $8.60 | 964K |
| Aug 18, 2026 | $7.81 | $8.265 | $7.81 | $8.18 | 710.44K |
| Aug 17, 2026 | $8.13 | $8.2312 | $7.72 | $7.77 | 614.48K |
| Aug 14, 2026 | $8.02 | $8.258 | $7.91 | $8.155 | 648.72K |
| Aug 13, 2026 | $8.11 | $8.335 | $8.00 | $8.02 | 778.37K |
| Aug 12, 2026 | $8.24 | $8.35 | $8.07 | $8.12 | 959.13K |
| Aug 11, 2026 | $7.68 | $8.43 | $7.55 | $8.34 | 2.79M |
| Aug 10, 2026 | $7.465 | $7.64 | $7.18 | $7.57 | 1.4M |
| Aug 7, 2026 | $7.28 | $7.80 | $7.21 | $7.59 | 1.63M |
| Aug 6, 2026 | $6.99 | $7.52 | $6.54 | $7.41 | 2.92M |
| Aug 5, 2026 | $6.13 | $6.235 | $6.02 | $6.18 | 1.16M |
| Aug 4, 2026 | $6.10 | $6.18 | $5.93 | $6.12 | 668.34K |
| Aug 3, 2026 | $5.91 | $6.06 | $5.835 | $6.05 | 587.03K |
Latest EOLS news
The latest Smart Investors Daily articles mentioning EOLS.
Stock researchCompany · Overview
EOLS research
Overview
Company profile and research snapshot.
Company profile
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $19.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 25, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 17, 2026 | BTIG | Buy | — |
| Mar 4, 2026 | BTIG | Buy | — |
| Feb 3, 2026 | HC Wainwright & Co. | Buy | — |
| Jan 22, 2026 | BTIG | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Mar 4, 2026
BTIG Reiterates Buy on Evolus, Maintains $13 Price Target
BTIG analyst Sam Eiber reiterates Evolus (NASDAQ:EOLS) with a Buy and maintains $13 price target.
SeekingAlpha · Mar 4, 2026
Evolus, Inc. (EOLS) Q4 2025 Earnings Call Transcript
ChartMill · Mar 3, 2026
Evolus Inc (NASDAQ:EOLS) Reports Q4 2025 Earnings Beat and Path to 2026 Profitability
Evolus reports Q4 2025 earnings beat, revenue growth, and a path to sustainable profitability beginning in 2026.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
